APA (7th ed.) Citation

Choi, Y. J., Lee, Y. C., Kim, J. M., Kim, J. I., Moon, J. S., Lim, Y. J., . . . Jang, J. Y. (2022). Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial. Gut and liver, 16(4), 535-546. https://doi.org/10.5009/gnl220055

Chicago Style (17th ed.) Citation

Choi, Yoon Jin, et al. "Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter Pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial." Gut and Liver 16, no. 4 (2022): 535-546. https://doi.org/10.5009/gnl220055.

MLA (9th ed.) Citation

Choi, Yoon Jin, et al. "Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter Pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial." Gut and Liver, vol. 16, no. 4, 2022, pp. 535-546, https://doi.org/10.5009/gnl220055.